At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 93 enrolled
Drug / intervention
Clopidogrel +2 moredrug
Likely dose
Aspirin 81 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications
In Brief
A Phase 3 clinical trial evaluating Clopidogrel, Aspirin 81 mg, and 1 other intervention for Stroke and Myocardial Infarctions. Completed, enrolled 93 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Myocardial Infarctions
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
Primary CompletionApr 2010
Study CompletionDec 2011
First PostedApr 2012
TodayJul 2026
First PostedApr 27, 2012
Enrollment StartJul 1, 2007
Primary CompletionApr 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.2 years ago
Interventions
Clopidogreldrug
Clopidogrel 75 mg QD
Aspirin 81 mgdrug
Aspirin 81mg QD
Aspirin >300 mgdrug
Aspirin \>300 mg QD